Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GCK | P35557 | 3/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392793 | 0.97 | DEGS1 (0.50) | DEGS1KMT2AMEN1RECQLGCK | |
| SCHEMBL2397116 | 0.87 | HCAR3 (0.58) | DEGS1GCKHCAR3RAB9ANPC1 | |
| SCHEMBL2396270 | 0.84 | HCAR3 (0.56) | DEGS1GCKHCAR3RAB9ANPC1 | |
| SCHEMBL2396155 | 0.82 | PTPN1 (0.51) | DEGS1KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL2397298 | 0.82 | MEN1 (0.46) | DEGS1KMT2AMEN1RECQLGCK | |
| SCHEMBL2394759 | 0.82 | MAPK1 (0.49) | KMT2AMEN1RAB9ANPC1TP53 | |
| SCHEMBL2393644 | 0.79 | NPC1 (0.50) | DEGS1KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL2393663 | 0.79 | MAPKAPK2 (0.47) | KMT2AMEN1RAB9ANPC1TP53 | |
| SCHEMBL2392565 | 0.79 | MAPK1 (0.48) | KMT2AMEN1RAB9ANPC1TP53 | |
| SCHEMBL2394634 | 0.79 | MAPK1 (0.48) | KMT2AMEN1RAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2189443-B1 | TRICYCLIC AMIDE COMPOUND | RES FOUND ITSUU LAB (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-8232300-B2 | Tricyclic amide compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232300-B2 | Tricyclic amide compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232300-B2 | Tricyclic amide compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2189443-A1 | TRICYCLIC AMIDE COMPOUND | Research Foundation Itsuu Laboratory (JP) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RXRA, RXRB, RXRG | DEGS1 788/4885KMT2A 1560/4885MEN1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.